Neural Pattern Recognition
Our proprietary AI models are trained on over 10,000 CNS trials spanning two decades. We identify success patterns that traditional statistical methods miss.
Platform
Comprehensive AI-powered tools designed specifically for neurological and psychiatric drug development.
Section 01
Our proprietary AI models are trained on over 10,000 CNS trials spanning two decades. We identify success patterns that traditional statistical methods miss.
Forecast trial outcomes with 73% accuracy using multi-modal data integration including biomarkers, patient demographics, and protocol designs.
Automatically flag red flags in trial design, patient selection criteria, and endpoint choices that have historically led to failure in similar CNS indications.
Section 02
Access curated data from Alzheimer’s, Parkinson’s, ALS, depression, schizophrenia, and 50+ other neurological and psychiatric indications.
Cross-reference your biomarkers against thousands of successful and failed trials to identify predictive signals for efficacy and safety.
Our database is continuously updated with new trial results, regulatory decisions, and published research to keep insights current.
Section 03
Generate data-driven recommendations for patient inclusion/exclusion criteria, primary endpoints, dose selection, and trial duration.
Share insights, annotations, and reports across clinical development, medical affairs, and executive teams with role-based permissions.
Create investor-ready or regulatory-focused reports in minutes, complete with visualizations and supporting evidence.
Section 04
SOC 2 Type II certified infrastructure with AES-256 encryption at rest and TLS 1.3 in transit.
Full HIPAA compliance for handling patient-level data with audit trails, access logs, and automated data retention policies.
Our analytical methods and AI models have been reviewed and validated by FDA statisticians for use in regulatory submissions.
Get Started
Schedule a personalized demo to see how Genivra can transform your CNS trial strategy.